Informations

Liver cancer is the third leading cause of cancer death in China. In recent years, the application of targeted and immunotherapies has improved the survival of liver cancer patients. However, due to the high molecular heterogeneity of liver cancer, there is still a lack of biological markers for predicting clinical efficacy, and there is a…

Liver cancer has become the 6th most common and the 3rd leading cause of cancer deaths worldwide. For liver cancer patients, surgery is the preferred method to completely eliminate tumors and achieve long-term survival. However, the majority of liver cancer patients still face late diagnoses and low survival rates. In recent years, the systemic treatment…

The diagnosis of liver cancer involves three aspects, including imaging, blood test results, and biopsy pathology results. Typically, the diagnosis of a tumor is confirmed only under a microscope after obtaining pathological tissue. However, liver cancer has its unique characteristics, and its diagnosis can be based on cirrhosis and confirmed through imaging tests such as…

In recent years, there has been rapid progress in the systemic treatment of liver cancer, with new immunotherapies and targeted therapies continually emerging. This has also driven ongoing innovation in the concepts and approaches for treating HCC. From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Experts Conference (APPLE 2023) was held…

Hepatocellular carcinoma (HCC) is one of the most common malignancies in China, with most patients diagnosed in the intermediate to advanced stages. The formation of portal vein tumor thrombus (PVTT) is a critical indicator of HCC progression, and patients with HCC combined with PVTT have a very poor prognosis. Previous studies have shown that low-dose…